IBU Access & Value Lead, Dengue
Bengaluru, Karnataka Job ID R0194554 Category Market Access Subcategory Market Access,Market Access Business Unit Global Portfolio Division Job Type Full timeBy clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms of Use. I further attest that all information I submit in my employment application is true to the best of my knowledge.
Job Description
About the Role
At this pivotal moment for Takeda, the International Business Unit (IBU) seeks a Director who will lead the development and deployment of compelling, evidence-based global market access value communications and co-lead external advisory and stakeholder engagement supporting Qdenga access, reimbursement, recommendation and adoption.
The Director will shape launch and lifecycle decisions by translating clinical, epidemiological and health economic evidence into differentiated payer value propositions; co-leading global NITAG and supranational advisory engagement, including WHO SAGE, PAHO SAG and other relevant advisory bodies; and establishing a continuous feedback loop so external insights inform access strategy, evidence priorities and execution at supranational, regional and local levels.
How you will contribute:
Global market access value communications
- Lead the evolution of global value propositions, Global Value Dossiers, payer narratives, objection handlers and supporting access materials.
- Translate clinical, epidemiological, health economic and real-world evidence into clear, compelling and differentiated value messages for payer, HTA, NITAG, national immunization programme and supranational audiences.
- Partner with Global Health Economics and other evidence functions to ensure evidence is accurately integrated into the Qdenga access narrative.
- Enable appropriate regional and local adaptation while maintaining consistency with the global value strategy.
- Maintain a coordinated document-development plan and reusable evidence base, with clear ownership, version control and update triggers, to prevent duplication and support efficient regional and LOC adaptation.
Engagement
- Co-lead the global strategy for engagement with NITAGs and supranational advisory bodies, including WHO SAGE, PAHO SAG and other relevant technical advisory groups, in partnership with Medical Affairs and other accountable functions.
- Co-Lead the Global NITAG / HTA Task Force, ensuring rapid, coordinated and evidence-based responses to questions from NITAGs / HTAs and supranational bodies.
- Interpret formal recommendations and assessment outcomes, identify policy and access implications, and translate them into global, regional and market plans and evidence priorities.
- Monitor evolving recommendation landscape and translate insights from advisory interactions into implications for access strategy, evidence generation and market planning.
External stakeholder engagement and insight generation
- Develop and oversee the broader global external access stakeholder strategy, including stakeholder mapping, prioritization and purposeful engagement with payers, policy stakeholders, public-health decision-makers, health economists and implementation experts.
- Lead external advisory boards and structured consultations addressing priority access, evidence and value questions.
- Establish a systematic feedback loop that captures and synthesizes insights from advisory bodies and broader stakeholder engagement.
- Translate external insights into clear recommendations for value communications, evidence priorities, engagement planning and launch or lifecycle decisions.
Regional and LOC enablement, publications and thought leadership
- Translate the implications of supranational and national recommendations for regional, cluster and LOC access strategies.
- Partner with regional and LOC teams to translate anticipated and published recommendations into country-specific access and implementation plans, with clear owners, milestones and dependencies.
- Initiate readiness planning ahead of recommendation milestones, coordinating assessment of financing, evidence, supply and delivery requirements with the responsible functions.
- Equip regional and LOC teams with evidence, value narratives, engagement guidance, training and response materials aligned with global advisory outcomes.
- Support consistency between supranational positioning, NITAG engagement and local payer, reimbursement and implementation narratives.
- Lead or coordinate relevant publications and thought leadership initiatives and share external insights and best practices across the global access network.
- Track implementation progress with regional and LOC teams, identifying unresolved access barriers and coordinating action or escalation through the appropriate governance forums.
Cross-functional leadership, governance and delivery
- Establish clear roles, decision rights and ways of working across Medical Affairs, Epidemiology, Health Economics, Policy, Commercial, regional teams and LOCs.
- Provide cross-functional leadership for global access materials and engagement initiatives, ensuring clear objectives, accountabilities, timelines and quality standards.
- Manage external agencies, consultants and advisory activities, ensuring effective governance, quality and compliance.
- Proactively manage risks, dependencies and competing priorities to deliver critical access milestones.
- Track delivery and contribution to access outcomes, including use of global materials, progression of funding partnerships, implementation readiness and resolution of access barriers.
- Own coordination and follow-through for the agreed Market Access workstreams, with scientific approval, commercial decisions, funding commitments and country execution remaining with the designated accountable functions.
Preferred Qualifications:
- Advanced degree in public health, life sciences, health economics, health policy, market access or a related discipline.
- Significant experience in global or regional vaccines market access, payer value strategy, value communications or external stakeholder engagement within the pharmaceutical or biotechnology industry.
- Demonstrated experience developing Global Value Dossiers, payer value propositions and evidence-based access materials.
- Experience in strategic stakeholder engagement and cross-functional leadership involving NITAGs, supranational or regional advisory bodies, HTA organizations, payers Demonstrated ability to translate complex clinical, epidemiological and economic evidence into materials supporting advisory, policy and access decision-making.
- Demonstrated ability to translate complex clinical, epidemiological and economic evidence into materials supporting advisory, policy and access decision-making.
- Excellent communication, influencing and project-management skills, with the ability to operate effectively across a global matrix organization; fluent English, written and spoken.
- Experience in vaccines and preventive healthcare, ideally including dengue.
- Experience supporting WHO SAGE, PAHO SAG, NITAGs or comparable technical advisory bodies, with a strong understanding of vaccine recommendation and access pathways.
- Experience coordinating cross-functional preparation for external technical assessments, advisory meetings or policy consultations.
- Experience developing vaccine or public-health funding partnerships, investment cases or proposals involving public-sector funders, development finance institutions or other access partners.
- Experience managing external advisory boards, stakeholder-feedback mechanisms, publications or thought-leadership initiatives.
- Familiarity with vaccine access pathways and national immunization programmes across Europe, Latin America and Asia Pacific.
SCOPE OF SUPERVISION
The role provides cross-functional leadership across global, regional and local teams and oversees external agencies, consultants and advisory activities as required.
TRAVEL REQUIREMENTS
Domestic and international travel is required, approximately 10%.